1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
ImmuPharma plc

ImmuPharma plc

3.70
GBX
-0.01
(-0.40%)
3.12BMarket Cap
May 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.05
-0.03
-0.04
-0.05
-0.05
-0.05
-0.04
-0.03
-0.03
-0.01
-0.01
-0.01
- -
- -
Free Cash Flow per Basic Share
-0.05
-0.03
-0.05
-0.06
-0.03
-0.03
-0.03
-0.02
-0.02
-0.01
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.07
0.06
0.02
0.04
0.03
0.05
0.03
0.04
0.02
0.01
- -
- -
- -
- -
Tangible Book Value per Share
0.06
0.06
0.01
0.04
0.02
0.05
0.03
0.04
0.01
0.01
- -
- -
- -
- -
Basic Weighted Avg Shares
82
84
89
117
131
139
153
200
251
303
362
416
491
491
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-1,853.15
-5,972.11
-3,998.67
-4,807.88
-9,941.04
-8,061.14
-4,412.7
-4,359.84
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-3
-4
-5
-6
-7
-6
-7
-8
-4
-3
-2
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1,553.71
-5,100.97
-3,230.91
-4,136.06
-8,866.22
-7,858.31
-5,415.72
-6,906.55
- -
- -
- -
- -
- -
Working Capital
5
5
1
5
3
5
3
6
2
1
- -
-1
1
1
LT Debt
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
5
6
2
6
4
8
5
10
4
3
1
-1
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-53.39
-51.7
-105.4
-147.14
-136.47
-128.72
-95
-91.93
-116.2
-109.77
-163.24
- -
- -
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
416
500
503
Market Capitalization
5
11
31

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1
2
2
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-17.5%
-106.64%
-226.53%
Free Cash Flow
0.97%
0.41%
34.07%
Net Income, GAAP
-3.35%
-19.95%
-27.21%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.01
2025
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Timothy Paul McCarthy
Full Time Employees
7
Sector
Health technology
Industry
Pharmaceuticals: other
Address
One Bartholomew Close London GL United Kingdom EC1A 7BL
IPO Date
Oct 28, 2003
Website
immupharma.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
ImmuPharma PLC is a specialist biopharmaceutical company focused on the discovery and development of peptide-based therapeutics targeting autoimmune diseases, inflammation, anti-infectives and oncology; its lead product, P140 (formerly Lupuzor and forigerimod), comprises a first-in-class autophagy immunomodulator in late-stage development for systemic lupus erythematosus and chronic inflammatory demyelinating polyneuropathy, complemented by a next-generation companion diagnostic for precision patient identification and monitoring; the pipeline also features BioAMB, an improved peptide formulation of amphotericin-B addressing systemic antifungal limitations, and BioCin, an enhanced vancomycin analog effective against methicillin-resistant Staphylococcus aureus and Clostridium difficile infections. Founded in 1999 and headquartered in London, England, with research operations primarily in France including collaborations with CNRS, the company operates across the UK, Euronext Growth Brussels and targets global markets for high-unmet-need conditions characterized by immune dysregulation and resistant infections. Recent developments include the filing of a new P140 patent in September 2025 extending potential protection to 2045, the launch of a redesigned corporate website in October 2025 highlighting its autoimmune platform transformation, ongoing engagement with multiple potential commercial partners for P140 with deal completion now targeted for 2026 following positive due diligence responses, strengthened cash position into Q4 2026 from R&D tax credits, warrant exercises and enhanced Lanstead Capital receipts totaling approximately £2 million, alongside reaffirmation of no near-term fundraising needs.

Company News

Company News APIChatGPT

  • defenseworld.net

    ImmuPharma (LON:IMM) Stock Price Crosses Below 200 Day Moving Average – Should You Sell?

  • defenseworld.net

    ImmuPharma (LON:IMM) Trading Up 0.9% – Should You Buy?

  • defenseworld.net

    ImmuPharma (LON:IMM) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened